Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: Influence of adjuvants and maternal antibodies

Journal of Infectious Diseases

Volumn 179, Issue 6, 1999, Pages 1326-1333

  Siegrist, Claire Anne ^a,b,c   Plotnicky Gilquin, Hélène ^a,b   Córdova, Marco ^a,b   Berney, Monika ^a,b   Bonnefoy, Jean Yves ^a,b   Nguyen, Thien Ngoc ^a,b   Lambert, Paul Henri ^a,b   Power, Ultan F ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Centre d'Immunologie Pierre Fabre   (France)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE BBG2NA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; IMMUNOPROPHYLAXIS; LUNG INFECTION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANIMALS, NEWBORN; HN PROTEIN; IMMUNITY, MATERNALLY-ACQUIRED; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0032991675     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314778     Document Type: Article

References (41)

1. 1. Collins, PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott-Raven, 1996:1313-51.
2. 2. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98: 289-300.
3. 3. Martin AJ, Gardner PS, McQuillin J. Epidemiology of respiratory viral infection among pediatric inpatients over a six year period in northeast England. Lancet 1978;2:1035-8.
4. 4. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. J Pediatr 1981;98:708-15.
5. 5. Green M, Brayer AF, Schenkman KA, Wald ER. Duration of hospitalization in previously well infants with respiratory syncytial virus infection. Pediatr Infect Dis J 1989;8:601-5.
6. 6. Belshe RB, van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 1982;145:311-9.
7. 7. Murphy BR, Alling DW, Snyder MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986;24:894-8.
8. 8. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969;89:449-63.
9. 9. Kim HW, Leikin SL, Arrobio JO, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to RSV induced by inactivated vaccine or by infection. Pediatr Res 1976;10:75-8.
10. 10. Åkerlind-Stopner B, Utter G, Mufson MA, Orvell C, Lerner RA, Norrby E. A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop. J Virol 1990;64:5143-8.
11. 11. Trudel M, Nadon F, Seguin C, Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology 1991;185:749-57.
12. 12. Garcia O, Martin M, Dopazo J, et al. Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol 1994;68:5448-59.
13. 13. Makrides SC, Nygren PÅ, Andrews B, et al. Extended in vivo half-life of human soluble complement receptor type I fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 1996;277:534-42.
14. 14. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991;65:5425-34.
15. 15. Sjölander A, Nygren PÅ, Ståhl S, et al. The serum albumin-binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties. J Immunol Methods 1997;201:115-23.
16. 16. Libon C, Corvaia N, Haeuw JF, et al. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. Vaccine 1999;17:406-14.
17. 17. Wagner DK, Muelenaer P, Henderson FW, et al. Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F und G glycoproteins after first, second, and third infections. J Clin Microbiol 1989;27:589-92.
18. 18. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 1997;230:155-66.
19. 19. Brandt C, Power UF, Plotnicky-Gilquin H, et al. Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein HBG2Na. J Infect Dis 1997;176:884-91.
20. 20. Murby M, Samuelsson E, Nguyen TN, et al. Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur J Biochem 1995;230:38-44.
21. 21. Taylor G, Stott EJ, Hughes M, Collins AP. Respiratory syncytial virus infection in mice. Infect Immun 1984;43:649-55.
22. 22. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA. Partial correction of the TH1/TH2 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur J Immunol 1996;26:2666-70.
23. 23. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today 1993;14:281-4.
24. 24. Kovarik J, Siegrist CA. Immunity in early life. Immunol Today 1998;19: 150-2.
25. 25. Brandenburg AH, Groen J, van Steensel-Moll HA, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997;52:97-104.
26. 26. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur J Immunol 1996;26: 1489-96.
27. 27. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells and upon subsequent immunization induce their immune deviation: implications for antibody versus T cell mediated autoimmunity. J Exp Med 1996;183:1613-21.
28. 28. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity in neonatal mice. Science 1996;271:1728-30.
29. 29. Warris ME, Tsou C, Erdman DD, Zaki SR, Anderson LH. Respiratory syncytial viras infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996;70: 2852-60.
30. 30. Stott EJ, Taylor G, Ball LA, et al. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 1987;61: 3855-61.
31. 31. Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 1994;179: 81-9.
32. 32. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996;70:7783-91.
33. 33. Corvaia N, Tournier P, Nguyen TN, et al. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2Na, in aluminum hydroxide. J Infect Dis 1997;176:560-9.
34. 34. Plotnicky-Gilquin H, Huss T, Aubry JP, et al. Absence of immunopathology following respiratory syncytial virus (RSV) challenge of BALB/c mice immunized with BBG2Na, a recombinant RSV vaccine candidate. Virol (in press).
35. 35. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995;8:22-33.
36. 36. Bangham CR. Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. Immunology 1986;59:37-41.
37. 37. Prince GA, Horswood RL, Camargo E, Suffin SC, Chanock RM. Parenteral immunization with live respiratory syncytial virus is blocked in seropositive cotton rats. Infect Immun 1982;37:1074-8.
38. 38. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 1988;62:3907-10.
39. 39. Murphy BR, Prince GA, Collins PL, Hildreth SW, Paradiso PR. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV). Vaccine 1991;9: 185-9.
40. 40. Siegrist CA, Barrios C, Martinez X, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allow successful early prime-boost strategies in mice. Eur J Immunol 1998;28: 4138-48.
41. 41. Englund JA, Anderson EL, Reed GF, et. al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995;96:580-4.